Tsuneaki Yoshinaga

TL;DR: The results suggest the possibility of systemic ATTRwt amyloidosis diagnosis at an early stage by carefully examining patients with CTS and investigate clinical findings of a series of patients diagnosed with antemortem diagnosis.

TL;DR: Investigating the prevalence and clinical features of posttransplant CNS symptoms in patients with hereditary ATTR amyloidosis and their Pittsburgh compound B (PiB)–PET imaging correlates found 11C-PiB-PET is a useful diagnostic tool for ATTR-type CAA occurred frequently in posttrans transplant patients with long disease durations.

TL;DR: Quantitative analysis of 11C-PiB PET images may be useful in therapy evaluation and will reveal whether amyloid clearance is correlated with clinical response, as well as investigating the utility of Pittsburgh compound B (PiB) positron emission tomography (PET) imaging for evaluating whole-bodyAmyloid involvement in patients with systemic amyloidsosis.

TL;DR: A nationwide survey on CTX revealed an average 16.5-year diagnostic delay, and Therapeutic interventions that included chenodeoxycholic acid, HMG-CoA reductase inhibitor, and LDL apheresis reduced serum cholestanol level in all patients and improved clinical symptoms in 40.5% of patients.

TL;DR: Careful assessment for alacrima followed by molecular genetic analysis of AAAS should be considered in patients who show a combined phenotype of motor neuron disease and sensory/autonomic disturbance, even in elderly patients.